COMPANY
Novavax
FDA-approved therapeutic company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Maintenance Manager | Uppsala, Sweden | Oct 22, 2026 | Oct 23, 2026 |
| Senior Director, Facilities & Engineering | Uppsala, Sweden | Sep 23, 2026 | Oct 9, 2026 |
| Process Operator | Uppsala, Sweden | Sep 23, 2026 | Oct 9, 2026 |
| QA Specialist | Uppsala, Sweden | Sep 23, 2026 | Oct 9, 2026 |
| Senior Scientist Formulation | Uppsala, Sweden | Sep 23, 2026 | Oct 9, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (5 open jobs at last check). source ↗
- Trial start Phase 4: Efficacy and Safety of NVX-CoV2705 source ↗
- FDA FDA CBER noteworthy supplement: NUVAXOVID (covid-19 vaccine, adjuvanted) — BLA125817/6, Aug 27, 2025. Applicant at approval: Novavax, Inc. source ↗
- FDA FDA New drug/biologic (novel): NUVAXOVID (covid-19 vaccine, adjuvanted) — BLA125817, May 16, 2025. Applicant at approval: Novavax Inc. source ↗
- Trial start Phase 2/Phase 3: Lot Consistency Study of COVID-19 and Influenza Combination Vaccine source ↗
- Trial start Phase 3: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine source ↗
- Trial start 3: Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine source ↗
- Trial start Phase 3: A Strain Change Study for SARS-CoV-2 rS Vaccines source ↗
- Trial start Phase 4: Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States source ↗
- Trial start 2: Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines source ↗
- Trial start Phase 2/Phase 3: A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. source ↗
- Trial start 3: Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines source ↗
- Trial start 3: Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines source ↗
- Trial start Phase 2: A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine source ↗
- Trial start Phase 2/Phase 3: Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years source ↗
- Trial start Phase 3: Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults source ↗
- Trial start 3: Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines source ↗
- Trial start Phase 2: A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19) source ↗
- Trial start Phase 1/Phase 2: Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults source ↗
- Trial start Phase 1/Phase 2: Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine source ↗
- Trial start Phase 3: A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 source ↗
- Trial start Phase 3: A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom source ↗
- Trial start Phase 2: A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults source ↗
- Trial start Phase 1/Phase 2: Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant source ↗
- Trial start 3: Phase 3 Pivotal Trial of NanoFlu™ in Older Adults source ↗
Upcoming milestones
- Nov 18, 2026 (ESTIMATED) · Phase 4 · Efficacy and Safety of NVX-CoV2705 · NCT07086222
Open jobs 5
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Maintenance Manager | Uppsala, Sweden | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Senior Director, Facilities & Engineering | Uppsala, Sweden | Sep 23, 2026 | Oct 9, 2026 | Senior |
| Process Operator | Uppsala, Sweden | Sep 23, 2026 | Oct 9, 2026 | Entry |
| QA Specialist | Uppsala, Sweden | Sep 23, 2026 | Oct 9, 2026 | Mid |
| Senior Scientist Formulation | Uppsala, Sweden | Sep 23, 2026 | Oct 9, 2026 | Senior |
Clinical trials (lead sponsor) 47
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06291857 | A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine | Phase 3 | Completed | Dec 9, 2024 | Dec 24, 2025 (actual) |
| NCT06633835 | Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States | Phase 4 | Completed | Sep 19, 2024 | Dec 30, 2024 (actual) |
| NCT05468736 | Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years | Phase 2/Phase 3 | Completed | Jul 22, 2022 | Jan 16, 2024 (actual) |
| NCT07086222 | Efficacy and Safety of NVX-CoV2705 | Phase 4 | Active, not recruiting | Nov 20, 2025 | Nov 18, 2026 (estimated) |
| NCT05463068 | Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults | Phase 3 | Completed | Jul 11, 2022 | Aug 17, 2022 (actual) |
| NCT06409663 | A Strain Change Study for SARS-CoV-2 rS Vaccines | Phase 3 | Completed | Oct 14, 2024 | Oct 15, 2024 (actual) |
| NCT05973006 | Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines | 3 | Completed | Aug 16, 2023 | Apr 1, 2024 (actual) |
| NCT05875701 | Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines | 3 | Completed | Mar 28, 2023 | Nov 11, 2023 (actual) |
| NCT04583995 | A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom | Phase 3 | Completed | Sep 28, 2020 | Mar 29, 2022 (actual) |
| NCT02624947 | A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization | Phase 3 | Completed | 2015-12 | Dec 28, 2018 (actual) |
| NCT04961541 | Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine | Phase 1/Phase 2 | Completed | Sep 8, 2021 | Dec 22, 2021 (actual) |
| NCT06482359 | Lot Consistency Study of COVID-19 and Influenza Combination Vaccine | Phase 2/Phase 3 | Withdrawn | Feb 1, 2025 | Nov 16, 2025 (estimated) |
| NCT06485752 | Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine | 3 | Withdrawn | 2024-11 | Feb 4, 2025 (actual) |
| NCT05925127 | Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines | 2 | Completed | Oct 16, 2023 | May 21, 2024 (actual) |
| NCT05519839 | A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine | Phase 2 | Completed | Dec 30, 2022 | Jul 25, 2023 (actual) |
| NCT05975060 | A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. | Phase 2/Phase 3 | Completed | Sep 7, 2023 | Nov 15, 2023 (actual) |
| NCT05372588 | Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines | 3 | Completed | May 25, 2022 | Jul 17, 2022 (actual) |
| NCT04611802 | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | Phase 3 | Completed | Dec 27, 2020 | Apr 10, 2023 (actual) |
| NCT04120194 | Phase 3 Pivotal Trial of NanoFlu™ in Older Adults | 3 | Completed | Oct 14, 2019 | Oct 29, 2020 (actual) |
| NCT04368988 | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant | Phase 1/Phase 2 | Completed | May 25, 2020 | Jun 1, 2022 (actual) |
| NCT05112848 | A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19) | Phase 2 | Completed | Feb 28, 2022 | May 23, 2022 (actual) |
| NCT03293498 | Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu) | Phase 1/Phase 2 | Completed | Sep 18, 2017 | Mar 14, 2018 (actual) |
| NCT03658629 | Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults | 2 | Terminated | Sep 24, 2018 | Apr 26, 2019 (actual) |
| NCT02608502 | A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults | Phase 3 | Completed | 2015-11 | 2016-12 (actual) |
| NCT05029856 | Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults | Phase 1/Phase 2 | Withdrawn | Feb 4, 2022 | 2022-08 (estimated) |
| NCT02593071 | Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year. | Phase 2 | Completed | 2015-10 | 2016-11 (actual) |
| NCT02247726 | RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women. | Phase 2 | Completed | 2014-09 | 2016-07 (actual) |
| NCT02266628 | Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults | Phase 2 | Completed | 2014-10 | 2016-03 (actual) |
| NCT04533399 | A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults | Phase 2 | Completed | Aug 17, 2020 | Dec 7, 2021 (actual) |
| NCT03026348 | Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults | Phase 2 | Completed | 2017-01 | 2017-04 (actual) |
| NCT02370589 | Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects | Phase 1 | Completed | 2015-02 | 2016-04 (actual) |
| NCT02078674 | A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant | Phase 1/Phase 2 | Completed | 2014-03 | 2015-07 (actual) |
| NCT02307851 | Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults | Phase 2 | Completed | 2014-11 | 2015-06 (actual) |
| NCT01960686 | RSV F Dose-Ranging Study in Women | Phase 2 | Completed | 2013-10 | 2014-04 (actual) |
| NCT02296463 | A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age | I | Completed | 2014-11 | 2015-09 (actual) |
| NCT01897701 | A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1 | Phase 1 | Completed | 2013-07 | 2014-08 (actual) |
| NCT01704365 | RSV-F Vaccine Dose Ranging Study in Young Women | Phase 2 | Completed | 2012-10 | 2013-04 (actual) |
| NCT01709019 | RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly | Phase 1 | Completed | 2012-10 | 2013-07 (actual) |
| NCT01594320 | A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1 | Phase 1 | Completed | 2012-04 | 2012-07 (actual) |
| NCT01596725 | A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2 | Phase 1 | Completed | 2012-05 | 2012-08 (actual) |
| NCT00754455 | Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults | Phase 2 | Completed | 2008-09 | 2009-03 (actual) |
| NCT00903552 | Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) | Phase 2 | Completed | 2009-05 | 2009-10 (actual) |
| NCT01561768 | A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults | Phase 2 | Completed | 2012-03 | 2013-01 (actual) |
| NCT01014806 | Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults | Phase 2 | Completed | 2009-11 | 2010-05 (actual) |
| NCT00519389 | Safety, Reactogenicity and Immunogenicity of an H5N1 VLP | Phase 1/Phase 2 | Completed | 2007-07 | 2008-11 (actual) |
| NCT01072799 | Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine | Phase 2 | Completed | 2009-10 | 2012-03 (actual) |
| NCT01290419 | Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine | Phase 1 | Completed | 2010-12 | 2011-12 (actual) |
FDA records (last 2 years)
Connect
See your connections at Novavax on LinkedIn (search by name, results not checked)